by Mark Curtis | Feb 19, 2015
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...
by Mark Curtis | Feb 17, 2015
> The scientific community has long sought to uncover the identity of a true dermal stem cell. While many unique cell populations have been described in the literature, some of which are predictive of a dermal stem cell, the exact location and behavior of this cell...
by Lisa Willemse | Feb 13, 2015
> The blood stem cell (or hematopoietic stem cell as it’s known in scientific parlance) was the first stem cell to be identified, which makes it a bit of a celebrity, as stem cells go. Here in Canada, we like to think of Drs. James Till and Ernest McCulloch,...
by David Kent | Feb 9, 2015
> This article is the second in a series about the human capital created by the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. The first article focused on...
by Stacey Johnson | Feb 6, 2015
. In 2012, Deborah Lieu from the University of California, Davis was granted $1.3 million by the California Institute for Regenerative Medicine (CIRM) to develop pacemaking cells from human induced pluripotent stem cells (HiPSCs) to replace electronic pacemakers. I...
by David Kent | Feb 2, 2015
> As many of our readers are aware, the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. I have been a trainee/alumnus since the start of my PhD in 2003 and...
by Peter Raaymakers | Jan 30, 2015
Click image to go to CTV News Ottawa video We’ve written about some questionable “clinical trials” recruiting patients in Canada recently, so it only makes sense to follow-up with some hopeful news about a legitimate,...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Stacey Johnson | Jan 23, 2015
. Signals’ mandate is to bring you, dear reader, blogs about stem cells, commercialization and biomaterials, but lately there hasn’t been much of the latter; therefore, I’ve decided to try to fill that gap. But before you get too excited, I am in no way an expert on...
by Stacey Johnson | Jan 20, 2015
. Before you read my blog, I recommend that you first read Sara Nolte’s blog “Bad luck, bad science, or bad reporting?” In it, Sara does an excellent job explaining and commenting on Drs. Cristian Tomasetti’s and Bert Vogelstein’s study “Variation in cancer risk among...
Comments